Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3182-3190

  Hodi, F Stephen ^a   Corless, Christopher L ^d   Giobbie Hurder, Anita ^a   Fletcher, Jonathan A ^b   Zhu, Meijun ^b   Marino Enriquez, Adrian ^b   Friedlander, Philip ^a,e   Gonzalez, Rene ^f   Weber, Jeffrey S ^g   Gajewski, Thomas F ^h   O'Day, Steven J ⁱ   Kim, Kevin B ^j   Lawrence, Donald ^c   Flaherty, Keith T ^c   Luke, Jason J ^a   Collichio, Frances A ^k   Ernstoff, Marc S ^l   Heinrich, Michael C ^d   Beadling, Carol ^d   Zukotynski, Katherine A ^a   Yap, Jeffrey T ^a   Van Den Abbeele, Annick D ^a   Demetri, George D ^a   Fisher, David E ^c   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ Beverly Hills Cancer Center   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l DARTMOUTH MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; KIT PROTEIN; N RAS PROTEIN; ONCOPROTEIN; PROTON PUMP INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHRONICALLY SUN DAMAGED SKIN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; MALE; MASS SPECTROMETRY; MELANOMA; MIDDLE AGED; MUCOSA; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SKIN DEFECT; SUN; SUN EXPOSURE; TREATMENT RESPONSE; VERY ELDERLY; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; MORTALITY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SECONDARY; SKIN NEOPLASMS; SUNLIGHT; SURVIVAL RATE; DRUG EFFECT; METASTASIS; SKIN TUMOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHRONIC DISEASE; FEMALE; GENE AMPLIFICATION; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUCOUS MEMBRANE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SKIN NEOPLASMS; SUNLIGHT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84881512367     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.7836     Document Type: Article

References (32)

1. Mendenhall WM, Amdur RJ, Hinerman RW, et al: Head and neck mucosal melanoma. Am J Clin Oncol 28:626-630, 2005. (Pubitemid 41790018)
2. Tomicic J, Wanebo HJ: Mucosal melanomas. Surg Clin North Am 83:237-252, 2003. (Pubitemid 36514808)
3. Batsakis JG, Suarez P: Mucosal melanomas: A review. Adv Anat Pathol 7:167-180, 2000.
4. Stalkup JR, Orengo IF, Katta R: Controversies in acral lentiginous melanoma. Dermatol Surg 28: 1051-1059, 2002; discussion 1059. (Pubitemid 35424807)
5. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346, 2006. (Pubitemid 46630793)
6. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005. (Pubitemid 41653105)
7. Kong Y, Si L, Zhu Y, et al: Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17:1684-1691, 2011.
8. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-2334, 2011.
9. Handolias D, Salemi R, Murray W, et al: Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23:210-215, 2010.
10. Frost MJ, Ferrao PT, Hughes TP, et al: Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115-1124, 2002.
11. Jiang X, Zhou J, Yuen NK, et al: Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 14:7726-7732, 2008.
12. Thomas NE, Kricker A, From L, et al: Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis. Cancer Epidemiol Biomarkers Prev 19: 2932-2941, 2010.
13. Beadling C, Heinrich MC, Warrick A, et al: Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 13:504-513, 2011.
14. Beadling C, Jacobson-Dunlop E, Hodi FS, et al: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14:6821-6828, 2008.
15. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003. (Pubitemid 46621810)
16. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949- 954, 2002. (Pubitemid 34716871)
17. Fecher LA, Cummings SD, Keefe MJ, et al: Toward a molecular classification of melanoma. J Clin Oncol 25:1606-1620, 2007. (Pubitemid 46733089)
18. Berger MF, Garraway LA: Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am 23:397-414, 2009.
19. Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602, 2009.
20. Flaherty K: Advances in drug development: BRAF validation in melanoma. Clin Adv Hematol Oncol 8:31-34, 2010.
21. Wyman K, Atkins MB, Prieto V, et al: Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 106:2005-2011, 2006. (Pubitemid 43673217)
22. Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734-740, 2008.
23. Ugurel S, Hildenbrand R, Zimpfer A, et al: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398-1405, 2005. (Pubitemid 40705006)
24. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-2051, 2008.
25. Lutzky J, Bauer J, Bastian BC: Dosedependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-493, 2008. (Pubitemid 351990966)
26. Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-2909, 2011.
27. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002. (Pubitemid 34879334)
28. Chi P, Chen Y, Zhang L, et al: ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467:849- 853, 2010.
29. Gounder MM, Maki RG: Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 67:S25-S43, 2011 (suppl 1).
30. Todd JR, Scurr LL, Becker TM, et al: The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene 10.1038/onc.2012.562 [epub ahead of print on December 17, 2012].
31. Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012.
32. Demetri GD: Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST. Clin Adv Hematol Oncol 7:S6-S7, 2009.